News
JNJ
147.11
-0.96%
-1.42
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Neurocrine Biosciences, Inc. Achieved positive results from its phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with major depressive disorder. The drug may offer several advantages over existing treatment options. The global Major Depressive Disorder treatment market is expected to reach $14.96 billion by 2032. Neurocrine has already received FDA approval for a drug for Huntington's Disease. The company has several catalysts to look forward to.
Seeking Alpha · 2h ago
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Annual Meeting of the American Society of Clinical Oncology will be held in Chicago. The oral presentations will cover a range of topics including targeted therapies and immunologic therapies for various types of cancer. The plenary session will feature presentations on esophageal cancer, melanoma and lung cancer.
Seeking Alpha · 3h ago
Bert's March Dividend Income Summary
March is one of the lower months for SCHD for dividend payments. Realty Income has been one of my top stock buys in 2024. My wife and I earned almost $5,000 in passive income this month. 59% of our March Dividend Income came from funds.
Seeking Alpha · 7h ago
Guru Fundamental Report for JNJ
NASDAQ · 12h ago
March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys
March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys. Global stock indices continued an upward trend in March, with both U.S. Stocks rising by 3%. Nvidia unveiled its groundbreaking Blackwell chip at GTC 2024. The S&P 500 recorded its longest positive monthly streak since 2021.
Seeking Alpha · 13h ago
LLY vs. JNJ: Which Big Pharma Stock Is Better?
I evaluated two big pharma stocks, Eli Lilly and Johnson & Johnson, using TipRanks’ Comparison Tool. Shares of Eli Lilly have surged 26% year-to-date and are up 92% over the last 12 months. A neutral view for Eli Lilly suggests a bullish view for Johnson and Johnson. Eli Lilly is trading at a much higher valuation than JNJ.
TipRanks · 21h ago
Will Higher Keytruda Sales Drive Merck's Q1
NASDAQ · 23h ago
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset
Shares of Cidara Therapeutics are up 42% in after-hours trading. The company divested a candidiasis treatment to its partner and bought back the rights to an influenza-prevention treatment. The stock is up roughly 15-fold since the start of the year.
Dow Jones · 1d ago
Cidara Therapeutics Reacquires Global Development And Commercial Rights To CD388 From Johnson & Johnson For A One Time Payment Of $85M; Announces Private Placement Financing Of $240M
Cidara Therapeutics, Inc. Has entered into a definitive agreement with Johnson & Johnson to reacquire the exclusive global development and commercial rights to CD388. $240 million private placement financing led by RA Capital Management to fund Phase 2b clinical trial. CD388 is in development for the prevention of all strains of influenza A and B.
Benzinga · 1d ago
Cidara stock rallies amid $240M private placement, drug update
Shares of Cidara Therapeutics rallied 25% in post-market trading. The company announced it had reacquired rights to its antiviral drug CD388 from Johnson & Johnson. The drug is being developed as a treatment for influenza A and B. J&J also agreed to a $240M private placement of the company's stock.
Seeking Alpha · 1d ago
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
NASDAQ · 1d ago
Neurocrine Biosciences upgraded at Wells Fargo on pipeline
Wells Fargo upgraded Neurocrine Biosciences from equal weight to overweight on the strength of its pipeline. The firm also upped its price target to $170 from $140. Analyst believes the company's crinecerfont could be a $1.5B drug.
Seeking Alpha · 1d ago
Dow Movers: JNJ, BA
NASDAQ · 1d ago
The Zacks Analyst Blog Highlights KB Home, Interactive Brokers Group, Qualcomm and Johnson & Johnson
NASDAQ · 1d ago
March Readers Marked 20 Ideal-To-Buy Dividend Dogs
Home Dividends Analysis Dividend Quick Picks March Readers Marked 20 Ideal-To-Buy Dividending Dogs. Of the 32 stocks mentioned by Fly_dragonfly in their comments, 20 qualified as "ideal" for dividend-paying stocks. Two stocks made the top 20 list for the month of March.
Seeking Alpha · 1d ago
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
Three undervalued blue chip stocks you can buy for $5,000 or less and hold forever. Johnson & Johnson has paid and raised its dividend for 62 consecutive years. Altria Group is a tobacco company that's focusing on smokeless products. Realty Income is a great way to benefit from owning real estate.
The Motley Fool · 1d ago
Sanofi reportedly lining up banks for consumer products spinoff
Healthcare M&A Sanofi reportedly lining up banks for consumer products spinoff. French drugmaker has asked banks to submit proposals for a potential spinoff of its consumer health products division. The company is mulling whether to spin off the unit or sell it outright. A separate listing could be valued at over $20B.
Seeking Alpha · 2d ago
Baron Health Care Fund Q1 2024 Shareholder Letter
Baron Health Care Fund advanced 8.92% in the quarter ended March 31, 2024. The Fund's performance was in line with the Russell 3000 Health Care Index and the S&P 500 Index. Investments in health care equipment, pharmaceuticals, and life sciences added the most value in the period.
Seeking Alpha · 2d ago
4 Stocks to Watch on Their Recent Dividend Hikes
NASDAQ · 2d ago
Not A Millionaire? No Problem! Here's A 10-Stock Portfolio To Retire Comfortably
The retirement crisis may not be as bad as it seems, with most retirees doing fine with less savings than expected. The expected amount to retire comfortably in the United States is now north of $1.4 million. The average retirement savings for U.S. Adults is only $88,400. A low-risk portfolio consisting of dividend growth stocks can yield substantial returns in retirement.
Seeking Alpha · 2d ago
More
Webull provides a variety of real-time JNJ stock news. You can receive the latest news about Johnson & Johnson through multiple platforms. This information may help you make smarter investment decisions.
About JNJ
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, and vision fields. These products are distributed to wholesalers, hospitals, and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.